Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded at Kepler Capital Markets

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by stock analysts at Kepler Capital Markets from a “hold” rating to a “buy” rating in a report released on Wednesday,Briefing.com Automated Import reports.

BAYRY has been the topic of a number of other reports. Wall Street Zen raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. The Goldman Sachs Group raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 5th. Finally, Hsbc Global Res upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Monday, April 28th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Performance

OTCMKTS BAYRY opened at $7.62 on Wednesday. The company has a quick ratio of 0.81, a current ratio of 1.32 and a debt-to-equity ratio of 1.19. The company has a market capitalization of $29.94 billion, a P/E ratio of -29.31 and a beta of 0.85. Bayer Aktiengesellschaft has a 12-month low of $4.79 and a 12-month high of $8.58. The firm has a 50-day moving average price of $6.52 and a two-hundred day moving average price of $5.90.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings results on Tuesday, May 13th. The company reported $0.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. The company had revenue of $15.27 billion during the quarter, compared to the consensus estimate of $13.39 billion. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. Analysts anticipate that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.